Journal of Clinical Oncology
Articles in this Issue
Ethnic distribution and clinical impact of serum tumor marker abnormalities in metastatic breast cancer patients.
e13007 Background: Serum tumor markers (STMs) - CA15-3, CA27-29 and CEA - are commonly used for surveillance and metastati...
Integrated imaging cytology profiling system for rapid point-of-care molecular diagnosis of leptomeningeal metastasis in breast cancer.
3073 Background: Leptomeningeal metastasis (LM) from breast cancer has a poor prognosis (median survival ~4 months). Early...
Implementing clinical-scale multiscale spatial transcriptomics: Tumor architecture profiling in SCRUM-Japan MONSTAR-SCREEN-3.
3132 Background: Spatial interactions between tumor cells and the tumor microenvironment (TME) influence disease progressi...
ADAPT-T-DXd: Multi-institutional real-world study of dose-adapted trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
1106 Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial efficacy in HER2-positive and HER2-low metast...
Single-cell analysis of plasma cell–centered inflammatory–immunosuppressive niches and response to daratumumab in primary light-chain amyloidosis.
7553 Background: Primary light-chain amyloidosis (pAL) is a plasma cell disease in which clonal plasma cells produce misfo...
Comparative effectiveness in <i>MET</i> ex14 NSCLC: Outcomes from a propensity score–based analysis of 8 pooled real-world datasets (the TOGETHER study).
e20749 Background: MET ex14 skipping alterations in non-small cell lung cancer (NSCLC), recognized as...
Facility-level differences in treatment patterns and outcomes among patients aged ≥ 75 years with follicular lymphoma: A National Cancer Database analysis.
e19064 Background: Follicular lymphoma (FL) is one of the most common indolent non-Hodgkin lymphomas, typically affecting...
Evaluation of the safety and efficacy of TRC003 in metastatic triple-negative breast cancer: A prospective, open-label, multicenter, single-arm exploratory clinical trial.
TPS1161 Background: TRC003 (also named 225 Ac-TR2205) is a novel molecule of targe...
From rinse to result: Feasibility of genotyping core biopsy supernatant in lung cancer.
e20051 Background: Non-small cell lung cancer (NSCLC) patients require molecular testing, even in early stage, to inform t...
Clinical trial in progress: Phase I/II study of tebentafusp in combination with liver-directed therapies for the treatment of metastatic uveal melanoma.
TPS9596 Background: Uveal melanoma (UM) has a high rate of metastasis, most commonly to the liver. Tebentafusp-tebn (Tebe)...
STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.
TPS3184 Background: Replication stress (RS) creates cancer cell vulnerability to which the critical DNA damage response ki...
Tissue-specific programming of CD8 effector T cells in immune checkpoint inhibitor-associated vitiligo and anti-tumor immunity in melanoma.
e21503 Background: Immune checkpoint inhibitor (ICI) therapy targeting PD-1 and CTLA-4 (e.g., ipilimumab-nivolumab) has re...
Impact assessment of implementing evidence-based de-escalation strategies in early breast cancer management in South Africa.
e12744 Background: In South Africa, where oncology resources are limited, adopting evidence-based radiation and chemothera...
Trends in liver metastases at diagnosis among young adults with colorectal cancer: A SEER-based analysis, 2010–2022.
e15543 Background: Early-onset colorectal cancer (CRC) is increasing in incidence among young adults, yet contemporary tre...
CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)–positive breast cancer (TBCRC 070).
TPS1156 Background: Endocrine therapy (ET) in combination with targeted treatments can effectively treat metastatic ER-pos...
Cardiomyopathy mortality among U.S. adults with breast cancer: A 25-year CDC WONDER study.
e13139 Background: Cardiovascular disease is an increasingly recognized contributor to mortality among cancer patients. Ar...
A real-world analysis of ctDNA methylation-based histology prediction and associated clinical characteristics in non–small cell lung cancer (NSCLC).
8539 Background: The treatment of NSCLC differs by histologic subtype, though traditional histologic review faces several...
Disproportionate reporting of ischemic gastrointestinal injury associated with lenvatinib: A FAERS pharmacovigilance analysis.
e23416 Background: Vascular endothelial growth factor (VEGF)–targeted tyrosine kinase inhibitors (TKIs) are widely used ac...
Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry.
5095 Background: Androgen receptor pathway inhibitors (ARPIs) improve survival in metastatic hormone-sensitive prostate ca...
Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance A021602).
4178 Background: In the CABINET trial, CABO significantly prolonged progression-free survival (PFS) compared to placebo (P...
Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
5008 Background: The combination of PARP inhibitors with standard AA-P may offer enhanced antitumor activity over AA-P. We...
Intrapatient comparative analysis of tumor-informed ctDNA and ctHPV-DNA in patients with HPV-driven OPSCC.
6075 Background: The rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) is largely attributable to human pa...
Germline pathogenic/likely pathogenic (P/LP) variants in epithelial neuroendocrine neoplasms: The case for universal germline genetic testing.
4182 Background: Current National Comprehensive Cancer Network (NCCN) guidelines for germline testing in neuroendocrine ne...
Xerostomia following lutetium-177 PSMA radioligand therapy in metastatic prostate cancer: Associations with accelerated fatigue and dental treatment onset in a propensity-matched real-world analysis.
e24086 Background: Radioligand therapy (RLT) with lutetium-177 (177Lu)-labeled prostate-specific membrane antigen (PSMA) l...
Is language barrier a mere proxy?: Psychological distress among non–English-speaking prostate cancer patients receiving radiation therapy—A prospective cohort study.
5113 Background: Cancer patients experience depression and anxiety at elevated rates, with minority and non-English-speaki...